- Home
- CATX vs JCE Comparison
CATX vs JCE Comparison
Compare CATX & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- JCE
- Stock Information
- Founded
- CATX 1983
- JCE 2007
- Country
- CATX United States
- JCE United States
- Employees
- CATX N/A
- JCE N/A
- Industry
- CATX Medical/Dental Instruments
- JCE Trusts Except Educational Religious and Charitable
- Sector
- CATX Health Care
- JCE Finance
- Exchange
- CATX Nasdaq
- JCE Nasdaq
- Market Cap
- CATX 239.0M
- JCE 266.3M
- IPO Year
- CATX N/A
- JCE N/A
- Fundamental
- Price
- CATX $3.87
- JCE $15.59
- Analyst Decision
- CATX Strong Buy
- JCE
- Analyst Count
- CATX 10
- JCE 0
- Target Price
- CATX $12.90
- JCE N/A
- AVG Volume (30 Days)
- CATX 835.6K
- JCE 49.7K
- Earning Date
- CATX 11-11-2025
- JCE 01-01-0001
- Dividend Yield
- CATX N/A
- JCE 9.26%
- EPS Growth
- CATX N/A
- JCE N/A
- EPS
- CATX N/A
- JCE N/A
- Revenue
- CATX $1,235,000.00
- JCE N/A
- Revenue This Year
- CATX N/A
- JCE N/A
- Revenue Next Year
- CATX N/A
- JCE N/A
- P/E Ratio
- CATX N/A
- JCE N/A
- Revenue Growth
- CATX N/A
- JCE N/A
- 52 Week Low
- CATX $1.60
- JCE $11.64
- 52 Week High
- CATX $13.44
- JCE $14.28
- Technical
- Relative Strength Index (RSI)
- CATX 53.74
- JCE 47.42
- Support Level
- CATX $3.37
- JCE $15.45
- Resistance Level
- CATX $3.78
- JCE $15.70
- Average True Range (ATR)
- CATX 0.20
- JCE 0.25
- MACD
- CATX 0.04
- JCE -0.01
- Stochastic Oscillator
- CATX 66.14
- JCE 45.07
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.